NDAORALTABLETPriority Review
Approved
Apr 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
DOLOBID (diflunisal) by Merck & Co. is clinical pharmacology action dolobid is a non-steroidal drug with analgesic, anti-inflammatory and antipyretic properties. First approved in 1982.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOLOBID (diflunisal) is a non-steroidal anti-inflammatory drug (NSAID) and peripherally-acting non-narcotic analgesic approved in 1982. It works by inhibiting prostaglandin synthetase to reduce pain, inflammation, and fever in peripheral tissues. The drug is indicated for mild to moderate pain and inflammatory conditions.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), brand team resources are likely focused on cost management and generic transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Action Dolobid is a non-steroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance, and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic…
Worked on DOLOBID at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.